ERBB2 and neoplasm: Most notably, the HER2-targeted antibody drug conjugate trastuzumab deruxtecan (T-DXd) received a tumor agnostic FDA accelerated approval in 2024 for the treatment of patients with advanced solid tumors with HER2 3+ expression by immunohistochemistry, including urothelial cancers19.